Atomoxetine increases salivary cortisol in healthy volunteers

Abstract

It has been proposed that acute hypothalamo-pituitary-adrenal (HPA) axis challenge using noradrenergic drugs may be of utility in assessing the functional integrity of central noradrenaline pathways. Atomoxetine (formerly tomoxetine) is a highly selective noradrenaline reuptake inhibitor, which has recently been licensed for the treatment of attention deficit hyperactivity disorder (ADHD).

The aim of this study was to assess the effects of acute atomoxetine on salivary cortisol levels for the first time.

A total of 60 healthy male volunteers received 60 mg atomoxetine, 30 mg citalopram, or placebo per os in a double-blind parallel groups design (n = 20 per group). Salivary cortisol, blood pressure and pulse rates were recorded at baseline and at +1.0, +1.5, +2.5 and +3.5 hours after capsule administration.

60 mg atomoxetine led to highly significant increases in salivary cortisol and a moderate increase in pulse rate, in the absence of significant effects on blood pressure. 30 mg citalopram had no significant effects on cortisol or cardiovascular parameters.

These data support the utility of atomoxetine neuroendocrine chalenge for evaluating central noradrenaline pathways, which may be of future use in neuropsychiatric patient studies. Furthermore, the effects of atomoxetine on HPA axis function may have clinical implications given the use of this agent in the treatment of ADHD.

Keywords

ADHD hyperactivity impulsivity neuroendocrine HPA noradrenaline depression

Get full access to this article

View all access options for this article.

References

Aardal-Eriksson E. , Karlberg B.E. , Holm A.C. (1998) Salivary cortisol — an alternative to serum cortisol determinations in dynamic function tests . Clin Chem Lab Med 36(4): 215—222

Beck A.T. , Beamesderfer A. (1974) Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7(0): 151—169

Biederman J. , Spencer T. , Wilens T. (2004) Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder . Int J Neuropsychopharmacol 7(1): 77—97

Chamberlain S.R. , Sahakian B. (2005) Neuropsychological assessment of mood disorder . Clin Neuropsych Journ Treat Eval 2(3): 137—148

Chamberlain S.R. , Sahakian B.J. (2004) Cognition in mania and depression: psychological models and clinical implications . Curr Psych Rep 6(6): 451—458

Chamberlain S.R. , Muller U. , Blackwell A.D. , Clark L.T. , Robbins W. , Sahakian B.J. (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans . Science 311(5762): 861—863

Curtis A.L. , Bello N.T. , Connolly K.R. , Valentino R.J. (2002) Corticotropin-releasing factor neurones of the central nucleus of the amygdala mediate locus coeruleus activation by cardiovascular stress . J Neuroendocrinol 14(8): 667—682

Faraone S.V. , Biederman J. , Spencer T. , Michelson D. , Adler L. , Reimherr F. , Glatt S.J. (2005) Efficacy of atomoxetine in adult attentiondeficit/hyperactivity disorder: a drug-placebo response curve analysis . Behav Brain Funct 1: 16

Goodyer I.M. , Herbert J. , Altham P.M. , Pearson J. , Secher S.M. , Shiers H.M. (1996) Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation . Psychol Med 26(2): 245—256

10.

Goodyer I.M. , Herbert J. , Tamplin A. (2003) Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry . Psychol Med 33(4): 601—610

11.

Harris T.O. , Borsanyi S. , Messari S. , Stanford K. , Cleary S.E. , Shiers H.M. , Brown G.W. , Herbert J. (2000) Morning cortisol as a risk factor for subsequent major depressive disorder in adult women . Br J Psychiatry 177: 505—510

12.

Hennig J. , Lange N. , Haag A. , Rohrmann S. , Netter P. (2000) Reboxetine in a neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy volunteers scoring high on subclinical depression . Int J Neuropsychopharmacol 3(3): 193—201

13.

Hill S.A. , Taylor M.J. , Harmer C.J. , Cowen P.J. (2003) Acute reboxetine administration increases plasma and salivary cortisol . J Psychopharmacol 17(3): 273—275

14.

Kirschbaum C. , Hellhammer D.H. (1994) Salivary cortisol in psychoneuroendocrine research: recent developments and applications . Psychoneuroendocrinology 19(4): 313—333

15.

Lile J.A. , Stoops W.W. , Durell T.M. , Glaser P.E. , Rush C.R. (2006) Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans . Exp Clin Psychopharmacol 14(2): 136—147

16.

Lo M.S. , Ng M.L. , Azmy B.S. , Khalid B.A. (1992) Clinical applications of salivary cortisol measurements . Singapore Med J 33(2): 170—173

17.

Nadeem H S. , Attenburrow M J. , Cowen P J. (2004) Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses . Neuropsychopharmacology 29(9): 1699—1703

18.

Nelson H.E. (1982) National Adult Reading Test (NART): Test Manual . NFER-Nelson, Windsor

19.

Nutt D. , Middleton H. , Franklin M. (1987) The neuroendocrine effects of oral imipramine . Psychoneuroendocrinology 12(5): 367—375

20.

Plotsky P.M. (1987) Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection . Endocrinology 121(3): 924—930

21.

Sauer J.M. , Ring B.J. , Witcher J.W. (2005) Clinical pharmacokinetics of atomoxetine . Clin Pharmacokinet 44(6): 571—590

22.

Schule C. , Baghai T. , Schmidbauer S. , Bidlingmaier M. , Strasburger C J. , Laakmann G. (2004) Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects . Psychoneuroendocrinology 29(2): 185—200

23.

Schule C. , Baghai T.C. , Eser D. , Zwanzger P. , Jordan M. , Buechs R. , Rupprecht R. (2006) Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients . Psychopharmacology (Berl) 186(4): 601—611

24.

Seifritz E. , Baumann P. , Muller M.J. , Annen O. , Amey M. , Hemmeter U. , Hatzinger M. , Chardon F. , Holsboer-Trachsler E. (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe . Neuropsychopharmacology 14(4): 253—263

25.

Sheline Y.I. (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity . Biol Psychiatry 48(8): 791—800

26.

Stahl S.M. (2003) Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition . J Clin Psychiatry 64(2): 110—111

27.

Thomason C. , Michelson D. (2004) Atomoxetine — treatment of attention deficit hyperactivity disorder: beyond stimulants . Drugs Today (Barc) 40(5): 465—473

28.

Tse W.S. , Bond A.J. (2005) Sex differences in cortisol response to reboxetine . J Psychopharmacol 19(1): 46—50

29.

van Stegeren A. , Rohleder N. , Everaerd W. , Wolf O.T. (2006) Salivary alpha amylase as marker for adrenergic activity during stress: Effect of betablockade . Psychoneuroendocrinology 31(1): 137—141

30.

Varghese F.P. , Brown E.S. (2001) The Hypothalamic-Pituitary-Adrenal Axis in Major Depressive Disorder: A Brief Primer for Primary Care Physicians. Prim Care Companion J Clin Psychiatry 3(4): 151—155